ClinicalTrials.gg
RecruitingNCT07690189Updated Aug 20, 2026

Study of NTB-928 in R/R OC

A Phase 1 interventional study of NTB-928 in Relapsed/Refractory Ovarian Carcinoma, sponsored by TeneoSeven, Inc.. Recruiting at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by TeneoSeven, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
477th of 1,498
90 · median 47
Started
2026
with 64 others
Phase 1
547 of 1,779
73 open now
Primary completion
2028-06
later than 312 of 452 live
Registered
1,755th of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 477th largest by planned enrollment of the 1,498 interventional ones that give a count, is one of 65 that started in 2026, is one of 547 in phase 1, reaches primary completion later than 312 of the 452 other live ones, and was the 1,755th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

273 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are:

  • What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given?
  • How is NTB-928 processed by the body at different dose levels?
  • Does the immune system react to NTB-928 during treatment?
  • What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?
03

Conditions studied

  • Relapsed/Refractory Ovarian Carcinoma

Browse trials for

Keywords

  • Ovarian Cancer
  • Ovarian Carcinoma
  • High Grade Serous Ovarian Carcinoma
  • Endometrioid Ovarian Carcinoma
  • Low Grade Serous Ovarian Carcinoma
  • Ovarian Carcinosarcoma
  • Clear Cell Carcinoma of the Ovary
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Have a confirmed diagnosis of ovarian cancer, including high-grade serous, high-grade endometrioid, low-grade serous, or clear cell ovarian cancer, or carcinosarcoma of the ovary. Patients with mucinous carcinoma are not eligible.
  • Have ovarian cancer and have already received standard treatments known to provide benefit; participants are eligible if they have platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer (with clearly documented ineligibility for further platinum chemotherapy).
  • Are able to understand the study requirements and are willing to provide written
  • Are willing to use effective during the study and for a period after the last dose of study treatment, if of

Exclusion criteria

Exclusion Criteria:

  • Have another active cancer that could interfere with assessment of this study treatment
  • Have received another drug or certain cancer treatments within a recent period before starting this study
  • Are pregnant or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    NTB-928 Treatment

    Drug: NTB-928

Interventions

  • DrugNTB-928

    NTB-928 is an investigational study drug administered as an intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Number of dose-limiting toxicities (DLTs) within the first cycle of treatment with NTB-928

    Time frame: Up to 35 days

  2. Number of participants with adverse events (AEs) and serious adverse events (SAEs), by severity and relatedness to NTB-928

    Time frame: Up to approximately 3 years

  3. Maximum plasma concentration (Cmax)

    Time frame: Up to approximately 3 years

  4. Time to Cmax (Tmax)

    Time frame: Up to approximately 3 years

  5. Area under the plasma concentration-time curve (AUC) over the dosing interval (AUC0-T)

    Time frame: Up to approximately 3 years

  6. AUC from time zero to time t (AUC0-t)

    Time frame: Up to approximately 3 years

  7. AUC from time 0 extrapolated to infinity (AUC0-∞)

    Time frame: Up to approximately 3 years

  8. Terminal elimination half-life (t½)

    Time frame: Up to approximately 3 years

  9. Clearance (CL)

    Time frame: Up to approximately 3 years

  10. Terminal elimination rate constant (λz)

    Time frame: Up to approximately 3 years

  11. Volume of distribution (Vz)

    Time frame: Up to approximately 3 years

  12. Accumulation ratio (Rac) for Cmax and AUC, and trough concentration (Ctrough)

    Time frame: Up to approximately 3 years

  13. Number of participants with anti-drug antibodies (ADA) at baseline and after treatment

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Objective response rate (ORR), based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Up to approximately 3 years

  2. Duration of objective response (DOR), based on RECIST v1.1

    Time frame: Up to approximately 3 years

  3. Progression-free survival (PFS), based on RECIST v1.1

    Time frame: Up to approximately 3 years

  4. Overall survival (OS)

    Time frame: Up to approximately 3 years

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 24 months is below that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 8, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Feb 2029
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07690189
Lead sponsor
TeneoSeven, Inc.
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Jun 29, 2026
Primary completion
Jun 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Aug 20, 2026

Study contacts

Clinical Trial Information
Contact
clinicaltrial@92biotech.com
510-392-0929

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion